Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Sundar Jagannath
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Procedures
Chemicals & Drugs
Concepts & Ideas
Phenomena
Sign-in to see full Profile
Network (preview)
58
Barlogie, Bart
43
Tricot, Guido
41
Vesole, David
27
Spitzer, G
22
Siegel, David
18
Desikan, KR
16
Anderson, Kenneth
16
Singhal, Seema
14
Crowley, John
14
Dhodapkar, Madhav
13
Fassas, AB
13
Bracy, D
11
Richardson, Paul
11
Munshi, Nikhil
10
Mattox, Sandy
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Sundar Jagannath (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Jagannath Sundar; Durie Brian G M; Wolf Jeffrey Lee; Camacho Elber S; Irwin David; Lutzky Jose; McKinley Marti; Potts Phyllis; Gabayan Afshin Eli; Mazumder Amitabha; Crowley John; Vescio Robert
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
British journal of haematology 2009;146(6):619-26.
-
2009: Cheson Bruce D; Cortés Jorge E; Jagannath Sundar
Expanding our mission: Clinical Lymphoma, Myeloma & Leukemia.
Clinical lymphoma & myeloma 2009;9(4):266.
-
2009: Richardson Paul; Jagannath Sundar; Hussein Mohamad; Berenson James; Singhal Seema; Irwin David; Williams Stephanie F; Bensinger William; Badros Ashraf Z; Vescio Robert; Kenvin Laurie; Yu Zhinuan; Olesnyckyj Marta; Zeldis Jerome; Knight Robert; Anderson Kenneth C
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Blood 2009;114(4):772-8.
-
2009: Chanan-Khan Asher A; Niesvizky Ruben; Hohl Raymond J; Zimmerman Todd M; Christiansen Neal P; Schiller Gary J; Callander Natalie; Lister John; Oken Martin; Jagannath Sundar
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.
Leukemia & lymphoma 2009;50(4):559-65.
-
2009: Jagannath Sundar
New drugs in multiple myeloma and the significance of autologous stem cell transplants.
Clinical advances in hematology & oncology : H&O 2009;7(3):178-9.
-
2008: Jagannath Sundar; Barlogie Bart; Berenson James R; Siegel David S; Irwin David; Richardson Paul G; Niesvizky Ruben; Alexanian Raymond; Limentani Steven A; Alsina Melissa; Esseltine Dixie-Lee; Anderson Kenneth C
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
British journal of haematology 2008;143(4):537-40.
-
2008: Dhodapkar Kavita M; Barbuto Scott; Matthews Phillip; Kukreja Anjli; Mazumder Amitabha; Vesole David; Jagannath Sundar; Dhodapkar Madhav V
Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.
Blood 2008;112(7):2878-85.
-
2008: Jagannath Sundar
Pathophysiological underpinnings of multiple myeloma progression.
Journal of managed care pharmacy : JMCP 2008;14(7 Suppl):7-11.
-
2008: Jagannath Sundar
Treatment of patients with myeloma with comorbid conditions: considerations for the clinician.
Clinical lymphoma & myeloma 2008;8 Suppl 4():S149-56.
-
2008: Jagannath Sundar
Progress in multiple myeloma.
Clinical lymphoma & myeloma 2008;8(4):202-4.
-
2008: Chang David H; Deng Haiteng; Matthews Phillip; Krasovsky Joseph; Ragupathi Govind; Spisek Radek; Mazumder Amitabha; Vesole David H; Jagannath Sundar; Dhodapkar Madhav V
Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer.
Blood 2008;112(4):1308-16.
-
2008: van Rhee Frits; Dhodapkar Madhav; Shaughnessy John D; Anaissie Elias; Siegel David; Hoering Antje; Zeldis Jerome; Jenkins Bonnie; Singhal Seema; Mehta Jayesh; Crowley John; Jagannath Sundar; Barlogie Bart
First thalidomide clinical trial in multiple myeloma: a decade.
Blood 2008;112(4):1035-8.
-
2008: Lacy Martha Q; Alsina Melissa; Fonseca Rafael; Paccagnella M Luisa; Melvin Carrie L; Yin Donghua; Sharma Amarnath; Enriquez Sarano M; Pollak Michael; Jagannath Sundar; Richardson Paul; Gualberto Antonio
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(19):3196-203.
-
2008: Bhandari Meghana S; Mazumder Amitabha; Jagannath Sundar; Vesole David H
Association between renal cell carcinoma and plasma cell dyscrasias: a case series of six patients.
Clinical lymphoma & myeloma 2008;8(3):188-90.
-
2007: Jagannath Sundar
Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology.
Clinical lymphoma & myeloma 2007;7(8):518-23.
-
2007: Jagannath Sundar
Current standards for first-line therapy of multiple myeloma.
Clinical lymphoma & myeloma 2007;7 Suppl 5():S207-14.
-
2007: Kyle Robert A; Yee Gary C; Somerfield Mark R; Flynn Patrick J; Halabi Susan; Jagannath Sundar; Orlowski Robert Z; Roodman David G; Twilde Patricia; Anderson Kenneth;
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(17):2464-72.
-
2007: Spisek Radek; Charalambous Anna; Mazumder Amitabha; Vesole David H; Jagannath Sundar; Dhodapkar Madhav V
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Blood 2007;109(11):4839-45.
-
2007: Spisek Radek; Kukreja Anjli; Chen Lin-Chi; Matthews Phillip; Mazumder Amitabha; Vesole David; Jagannath Sundar; Zebroski Henry A; Simpson Andrew J G; Ritter Gerd; Durie Brian; Crowley John; Shaughnessy John D; Scanlan Matthew J; Gure Ali O; Barlogie Bart; Dhodapkar Madhav V
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
The Journal of experimental medicine 2007;204(4):831-40.
-
2007: Bhandari Meghana; Jagannath Sundar
Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma.
Clinical lymphoma & myeloma 2007;7(5):373-5.
-
2007: Kukreja Anjli; Hutchinson Aisha; Mazumder Amitabha; Vesole David; Angitapalli Revathi; Jagannath Sundar; O'connor Owen A; Dhodapkar Madhav V
Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
British journal of haematology 2007;136(1):106-10.
-
2007: Jagannath S; Richardson P G; Sonneveld P; Schuster M W; Irwin D; Stadtmauer E A; Facon T; Harousseau J-L; Cowan J M; Anderson K C
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(1):151-7.
-
2006: Richardson Paul G; Blood Emily; Mitsiades Constantine S; Jagannath Sundar; Zeldenrust Steven R; Alsina Melissa; Schlossman Robert L; Rajkumar S Vincent; Desikan K Raman; Hideshima Teru; Munshi Nikhil C; Kelly-Colson Kathleen; Doss Deborah; McKenney Mary L; Gorelik Svetlana; Warren Diane; Freeman Andrea; Rich Rebecca; Wu Anfang; Olesnyckyj Marta; Wride Kenton; Dalton William S; Zeldis Jerome; Knight Robert; Weller Edie; Anderson Kenneth C
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood 2006;108(10):3458-64.
-
2006: Barlogie Bart; Tricot Guido J; van Rhee Frits; Angtuaco Edguardo; Walker Ron; Epstein Joshua; Shaughnessy John D; Jagannath Sundar; Bolejack Vanessa; Gurley Jennifer; Hoering Antje; Vesole David; Desikan Raman; Siegel David; Mehta Jayesh; Singhal Seema; Munshi Nikhil C; Dhodapkar Madhav; Jenkins Bonnie; Attal Michel; Harousseau Jean-Luc; Crowley John
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
British journal of haematology 2006;135(2):158-64.
-
2006: Katzel Jed Abraham; Mazumder Amitabha; Jagannath Sundar; Vesole David H
Engraftment syndrome after hematopoietic stem cell transplantation in multiple myeloma.
Clinical lymphoma & myeloma 2006;7(2):151.
-
2006: Jagannath Sundar
Bortezomib dosing in relapsed multiple myeloma.
Clinical lymphoma & myeloma 2006;7(2):101-2.
-
2006: Kukreja Anjli; Hutchinson Aisha; Dhodapkar Kavita; Mazumder Amitabha; Vesole David; Angitapalli Revathi; Jagannath Sundar; Dhodapkar Madhav V
Enhancement of clonogenicity of human multiple myeloma by dendritic cells.
The Journal of experimental medicine 2006;203(8):1859-65.
-
2006: Schwab Chris; Jagannath Sundar
The role of thalidomide in multiple myeloma.
Clinical lymphoma & myeloma 2006;7(1):26-9.
-
2006: Jagannath Sundar; Richardson Paul G; Barlogie Bart; Berenson James R; Singhal Seema; Irwin David; Srkalovic Gordan; Schenkein David P; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Haematologica 2006;91(7):929-34.
-
2006: Richardson Paul G; Briemberg Hannah; Jagannath Sundar; Wen Patrick Y; Barlogie Bart; Berenson James; Singhal Seema; Siegel David S; Irwin David; Schuster Michael; Srkalovic Gordan; Alexanian Raymond; Rajkumar S Vincent; Limentani Steven; Alsina Melissa; Orlowski Robert Z; Najarian Kevin; Esseltine Dixie; Anderson Kenneth C; Amato Anthony A
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3113-20.
-
2006: Chang David H; Liu Nancy; Klimek Virginia; Hassoun Hani; Mazumder Amitabha; Nimer Stephen D; Jagannath Sundar; Dhodapkar Madhav V
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
Blood 2006;108(2):618-21.
-
2006: Jagannath Sundar
The safety and efficacy of bortezomib in relapsed multiple myeloma.
Clinical advances in hematology & oncology : H&O 2006;4(5):2-3; discussion 8; suppl 13.
-
2006: Richardson Paul; Jagannath Sundar; Colson Kathleen
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Clinical advances in hematology & oncology : H&O 2006;4(5):1; discussion 8; suppl 13.
-
2006: Taylor Lesley; Aziz Mohamed; Klein Paula; Mazumder Amitabha; Jagannath Sundar; Axelrod Deborah
Plasmacytoma in the breast with axillary lymph node involvement: a case report.
Clinical breast cancer 2006;7(1):81-4.
-
2006: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David H; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Anderson Kenneth C
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Cancer 2006;106(6):1316-9.
-
2006: San Miguel Jesús; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Glasmacher Axel; Jagannath Sundar; Lonial Sagar; Orlowski Robert Z; Sonneveld Pieter; Ludwig Heinz
A practical update on the use of bortezomib in the management of multiple myeloma.
The oncologist 2006;11(1):51-61.
-
2006: Mazumder Amitabha; Jagannath Sundar
Thalidomide and lenalidomide in multiple myeloma.
Best practice & research. Clinical haematology 2006;19(4):769-80.
-
2005: Lonial Sagar; Waller Edmund K; Richardson Paul G; Jagannath Sundar; Orlowski Robert Z; Giver Cynthia R; Jaye David L; Francis Dixil; Giusti Sara; Torre Claire; Barlogie Bart; Berenson James R; Singhal Seema; Schenkein David P; Esseltine Dixie-Lee W; Anderson Jessica; Xiao Hugh; Heffner Leonard T; Anderson Kenneth C;
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood 2005;106(12):3777-84.
-
2005: Jagannath Sundar
Novel agents in first-line therapy for myeloma.
Oncology (Williston Park, N.Y.) 2005;19(12):1551-4.
-
2005: Berenson James R; Jagannath Sundar; Barlogie Bart; Siegel David T; Alexanian Raymond; Richardson Paul G; Irwin David; Alsina Melissa; Rajkumar S Vincent; Srkalovic Gordon; Singhal Seema; Limentani Steven; Niesvizky Ruben; Esseltine Dixie L; Trehu Elizabeth; Schenkein David P; Anderson Kenneth
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer 2005;104(10):2141-8.
-
2005: Richardson Paul Gerard Guy; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Hideshima Teru; Xiao Hugh; Esseltine Dixie; Schenkein David; Anderson Kenneth C;
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood 2005;106(9):2977-81.
-
2005: Jagannath Sundar; Durie Brian G M; Wolf Jeffrey; Camacho Elber; Irwin David; Lutzky Jose; McKinley Marti; Gabayan Eli; Mazumder Amitabha; Schenkein David; Crowley John
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
British journal of haematology 2005;129(6):776-83.
-
2005: Jagannath Sundar
Treatment of myeloma in patients not eligible for transplantation.
Current treatment options in oncology 2005;6(3):241-53.
-
2005: Jagannath Sundar; Barlogie Bart; Berenson James R; Singhal Seema; Alexanian Raymond; Srkalovic Gordan; Orlowski Robert Z; Richardson Paul G; Anderson Jessica; Nix Darrell; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer 2005;103(6):1195-200.
-
2004: Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson P G; Niesvizky R; Alexanian R; Limentani S A; Alsina M; Adams J; Kauffman M; Esseltine D-L; Schenkein D P; Anderson K C
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
British journal of haematology 2004;127(2):165-72.
-
2004: Richardson Paul; Schlossman Robert; Jagannath Sundar; Alsina Melissa; Desikan Raman; Blood Emily; Weller Edie; Mitsiades Constantine; Hideshima Teru; Davies Faith; Doss Deborah; Freeman Andrea; Bosch Joan; Patin John; Knight Robert; Zeldis Jerome; Dalton William; Anderson Kenneth
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):875-82.
-
2003: Fassas Athanasios B-T; Barlogie Bart; Ward Susan; Jagannath Sundar; Vesole David; Mattox Sandy; Siegel David; Muwalla Firas; Zangari Maurizio; Anaissie Elias; Rhee Frits Van; Thertulien Raymond; Lee Choon-Kee; Desikan Raman; Arzumanian Varant; McCoy Jason; Tricot Guido
Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.
British journal of haematology 2003;123(3):484-9.
-
2003: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Alexanian Raymond; Siegel David; Orlowski Robert Z; Kuter David; Limentani Steven A; Lee Stephanie; Hideshima Teru; Esseltine Dixie-Lee; Kauffman Michael; Adams Julian; Schenkein David P; Anderson Kenneth C
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
-
2003: Shaughnessy John; Jacobson Joth; Sawyer Jeff; McCoy Jason; Fassas Athanasios; Zhan Fenghuang; Bumm Klaus; Epstein Joshua; Anaissie Elias; Jagannath Sundar; Vesole David; Siegel David; Desikan Raman; Munshi Nikhil; Badros Ashraf; Tian Erming; Zangari Maurizio; Tricot Guido; Crowley John; Barlogie Bart
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
Blood 2003;101(10):3849-56.
-
2003: Desikan Raman; Barlogie Bart; Sethi Rajesh; Toor Amir; Spoon Dan; Angtuaco Edward; Vanhemert Rudy; VijayaGopal Anantha; Singhal Seema; Mehta Jayesh; Jagannath Sundar; Munshi Nikhil; Zangari Maurizio; Fassas Athanassios; Tricot Guido; Anaissie Elias
Infection--an underappreciated cause of bone pain in multiple myeloma.
British journal of haematology 2003;120(6):1047-50.
-
2002: Desikan Raman; Veksler Yuliya; Raza Syed; Stokes Barry; Sabir Tariq; Li Zu Jun; Jagannath Sundar
Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.
British journal of haematology 2002;119(2):496-9.
-
2002: Desikan Raman; Li Zujun; Jagannath Sundar
Waldenström's macroglobulinaemia: current therapy and future approaches.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2002;16(3):201-7.
-
2001: Desikan K R; Tricot G; Munshi N C; Anaissie E; Spoon D; Fassas A; Toor A; Zangari M; Badros A; Morris C; Vesole D H; Siegel D; Jagannath S; Barlogie B
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone.
British journal of haematology 2001;112(1):242-7.
-
2000: Desikan R; Barlogie B; Sawyer J; Ayers D; Tricot G; Badros A; Zangari M; Munshi N C; Anaissie E; Spoon D; Siegel D; Jagannath S; Vesole D; Epstein J; Shaughnessy J; Fassas A; Lim S; Roberson P; Crowley J
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Blood 2000;95(12):4008-10.
-
2000: Desikan K R; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole D H; Jagannath S; Singhal S; Mehta J; Spoon D; Anaissie E; Barlogie B; Munshi N
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
Bone marrow transplantation 2000;25(5):483-7.
-
1999: Desikan R; Dhodapkar M; Siegel D; Fassas A; Singh J; Singhal S; Mehta J; Vesole D; Tricot G; Jagannath S; Anaissie E; Barlogie B; Munshi N C
High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia.
British journal of haematology 1999;105(4):993-6.
-
1999: Gale R P; Park R E; Dubois R W; Anderson K C; Audeh W M; Bergsagel D; Jagannath S; Kyle R A; Oken M M; Perlman M; Rifkin R M; Stone M J; Durie B
Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow autotransplants in newly diagnosed multiple myeloma.
Leukemia & lymphoma 1999;33(5-6):511-9.
-
1999: Fassas A; Jagannath S; Desikan K R; Shah H R; Shaver R; Waldron J; Munshi N C; Barlogie B; Tricot G
Lymphomatoid granulomatosis following autologous stem cell transplantation.
Bone marrow transplantation 1999;23(1):79-81.
-
1999: Barlogie B; Jagannath S; Desikan K R; Mattox S; Vesole D; Siegel D; Tricot G; Munshi N; Fassas A; Singhal S; Mehta J; Anaissie E; Dhodapkar D; Naucke S; Cromer J; Sawyer J; Epstein J; Spoon D; Ayers D; Cheson B; Crowley J
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Blood 1999;93(1):55-65.
-
1998: Dhodapkar M V; Weinstein R; Tricot G; Jagannath S; Parfitt A M; Manolagas S C; Barlogie B
Biologic and therapeutic determinants of bone mineral density in multiple myeloma.
Leukemia & lymphoma 1998;32(1-2):121-7.
-
1998: Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
Bone marrow transplantation 1998;21(11):1101-7.
-
1998: Tricot G; Gazitt Y; Leemhuis T; Jagannath S; Desikan K R; Siegel D; Fassas A; Tindle S; Nelson J; Juttner C; Tsukamoto A; Hallagan J; Atkinson K; Reading C; Hoffman R; Barlogie B
Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.
Blood 1998;91(12):4489-95.
-
1998: Mehta J; Tricot G; Jagannath S; Ayers D; Singhal S; Siegel D; Desikan K; Munshi N; Fassas A; Mattox S; Vesole D; Crowley J; Barlogie B
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
Bone marrow transplantation 1998;21(9):887-92.
-
1998: Zent C S; Wilson C S; Tricot G; Jagannath S; Siegel D; Desikan K R; Munshi N; Bracy D; Barlogie B; Butch A W
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.
Blood 1998;91(9):3518-23.
-
1998: Desikan K R; Barlogie B; Jagannath S; Vesole D H; Siegel D; Fassas A; Munshi N; Singhal S; Mehta J; Tindle S; Nelson J; Bracy D; Mattox S; Tricot G
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1547-53.
-
1998: Sawyer J R; Tricot G; Mattox S; Jagannath S; Barlogie B
Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin.
Blood 1998;91(5):1732-41.
-
1998: Desikan K R; Jagannath S; Siegel D; Nelson J; Bracy D; Barlogie B; Tricot G
Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma.
Leukemia & lymphoma 1998;28(5-6):501-8.
-
1998: Barlogie B; Jagannath S; Tricot G; Desikan K R; Fassas A; Siegel D
Advances in the treatment of multiple myeloma.
Advances in internal medicine 1998;43():279-320.
-
1997: Dhodapkar M V; Jagannath S; Vesole D; Munshi N; Naucke S; Tricot G; Barlogie B
Treatment of AL-amyloidosis with dexamethasone plus alpha interferon.
Leukemia & lymphoma 1997;27(3-4):351-6.
-
1997: Desikan K R; Dhodapkar M V; Hough A; Waldron T; Jagannath S; Siegel D; Barlogie B; Tricot G
Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.
Leukemia & lymphoma 1997;27(3-4):315-9.
-
1997: Jagannath S; Vesole D H; Zhang M; Desikan K R; Copeland N; Jagannath M; Bracy D; Jones R; Crowley J; Tricot G; Barlogie B
Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma.
Bone marrow transplantation 1997;20(6):445-50.
-
1997: Mehta J; Tricot G; Jagannath S; Desikan K R; Siegel D; Singhal S; Munshi N; Vesole D; Mattox S; Bracy D; Barlogie B
High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant.
Bone marrow transplantation 1997;20(2):113-6.
-
1997: Guba S C; Vesole D H; Jagannath S; Bracy D; Barlogie B; Tricot G
Peripheral stem cell mobilization and engraftment in patients over age 60.
Bone marrow transplantation 1997;20(1):1-3.
-
1997: Tricot G; Sawyer J R; Jagannath S; Desikan K R; Siegel D; Naucke S; Mattox S; Bracy D; Munshi N; Barlogie B
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2659-66.
-
1997: Barlogie B; Jagannath S; Vesole D H; Naucke S; Cheson B; Mattox S; Bracy D; Salmon S; Jacobson J; Crowley J; Tricot G
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.
Blood 1997;89(3):789-93.
-
1997: Barlogie B; Jagannath S; Epstein J; Munshi N; Siegel D; Desikan K R; Feinman R; Hsu P L; von Bremen K; Tricot G
Biology and therapy of multiple myeloma in 1996.
Seminars in hematology 1997;34(1 Suppl 1):67-72.
-
1996: Govindarajan R; Jagannath S; Flick J T; Vesole D H; Sawyer J; Barlogie B; Tricot G
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma.
British journal of haematology 1996;95(2):349-53.
-
1996: Vesole D H; Tricot G; Jagannath S; Desikan K R; Siegel D; Bracy D; Miller L; Cheson B; Crowley J; Barlogie B
Autotransplants in multiple myeloma: what have we learned?
Blood 1996;88(3):838-47.
-
1996: Tricot G; Alberts D S; Johnson C; Roe D J; Dorr R T; Bracy D; Vesole D H; Jagannath S; Meyers R; Barlogie B
Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):947-52.
-
1996: Tricot G; Jagannath S; Vesole D H; Bracy D; Desikan K R; Siegel D; Barlogie B
Hematopoietic stem cell transplants for multiple myeloma.
Leukemia & lymphoma 1996;22(1-2):25-36.
-
1996: Tricot G; Vesole D H; Jagannath S; Hilton J; Munshi N; Barlogie B
Graft-versus-myeloma effect: proof of principle.
Blood 1996;87(3):1196-8.
-
1996: Gazitt Y; Tian E; Barlogie B; Reading C L; Vesole D H; Jagannath S; Schnell J; Hoffman R; Tricot G
Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor.
Blood 1996;87(2):805-11.
-
1996: Vesole D H; Jagannath S; Tricot G; Desikan K R; Siegel D; Barlogie B
Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma.
Cancer investigation 1996;14(4):378-91.
-
1996: Tricot G J; Naucke S; Vaught L; Vesole D; Jagannath S; Barlogie B
Is the risk of multiple myeloma increased in patients with silicone implants?
Current topics in microbiology and immunology 1996;210():357-9.
-
1995: Tricot G; Barlogie B; Jagannath S; Bracy D; Mattox S; Vesole D H; Naucke S; Sawyer J R
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.
Blood 1995;86(11):4250-6.
-
1995: Tricot G; Jagannath S; Vesole D H; Crowley J; Barlogie B
Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.
Bone marrow transplantation 1995;16(1):7-11.
-
1995: Gazitt Y; Reading C C; Hoffman R; Wickrema A; Vesole D H; Jagannath S; Condino J; Lee B; Barlogie B; Tricot G
Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.
Blood 1995;86(1):381-9.
-
1995: Barlogie B; Jagannath S; Vesole D; Tricot G
Autologous and allogeneic transplants for multiple myeloma.
Seminars in hematology 1995;32(1):31-44.
-
1995: Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
Blood 1995;85(2):588-96.
-
1994: Vesole D H; Jagannath S; Glenn L D; Barlogie B
Effect of low-dose granulocyte-macrophage colony-stimulating factor (LD-GM-CSF) on platelet transfusion-dependent thrombocytopenia.
American journal of hematology 1994;47(3):203-7.
-
1994: Jagannath S; Vesole D H; Tricot G; Crowley J; Salmon S E; Barlogie B
Hemopoietic stem cell transplants for multiple myeloma.
Oncology (Williston Park, N.Y.) 1994;8(11):89-103; discussion 103-6.
-
1994: Vesole D H; Barlogie B; Jagannath S; Cheson B; Tricot G; Alexanian R; Crowley J
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.
Blood 1994;84(3):950-6.
-
1994: Dimopoulos M A; Yau J C; Huan S D; Jagannath S; Spitzer G; Spinolo J A; Zagars G K; LeMaistre C F; Dicke K A; Zander A R
Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation.
American journal of hematology 1994;46(2):82-6.
-
1994: Barlogie B; Jagannath S; Vesole D; Tricot G
Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma.
Journal of hematotherapy 1994;3(2):149-53.
-
1993: Bierman P J; Bagin R G; Jagannath S; Vose J M; Spitzer G; Kessinger A; Dicke K A; Armitage J O
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(9):767-73.
-
1993: Vesole D H; Jagannath S; Glenn L; Barlogie B
Autotransplantation in multiple myeloma.
Hematology/oncology clinics of North America 1993;7(3):613-30.
-
1993: Spinolo J A; Jagannath S; Velásquez W; Spitzer G; Cabanillas F; Hagemeister F; Horwitz L J; Dicke K A
Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Leukemia & lymphoma 1993;9(1-2):71-7.
-
1992: Jagannath S; Vesole D H; Glenn L; Crowley J; Barlogie B
Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.
Blood 1992;80(7):1666-72.
-
1992: Jagannath S; Barlogie B
Autologous bone marrow transplantation for multiple myeloma.
Hematology/oncology clinics of North America 1992;6(2):437-49.
-
1992: Spinolo J A; Yau J C; Dicke K A; Scott E; Jagannath S; Horwitz L J; Spitzer G; Zander A R
Second bone marrow transplants for relapsed leukemia.
Cancer 1992;69(2):405-9.
-
1992: Barlogie B; Jagannath S
Autotransplants in myeloma.
Bone marrow transplantation 1992;10 Suppl 1():37-44.
-
1991: Kantarjian H M; Talpaz M; LeMaistre C F; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth A B
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Cancer 1991;67(12):2959-65.
-
1991: Velasquez W S; Fuller L M; Jagannath S; Tucker S L; North L B; Hagemeister F B; McLaughlin P; Swan F; Redman J R; Rodriguez M A
Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy.
Blood 1991;77(5):942-7.
-
1990: Jagannath S; Barlogie B; Dicke K; Alexanian R; Zagars G; Cheson B; Lemaistre F C; Smallwood L; Pruitt K; Dixon D O
Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.
Blood 1990;76(9):1860-6.
-
1990: Spinolo J A; Dicke K A; Horwitz L J; Jagannath S; McCredie K; Estey E; Kantarjian H; Zander A R; Keating M; Spitzer G
High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission.
Cancer 1990;66(4):619-26.
-
1990: Barlogie B; Jagannath S; Dixon D O; Cheson B; Smallwood L; Hendrickson A; Purvis J D; Bonnem E; Alexanian R
High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.
Blood 1990;76(4):677-80.
-
1990: Dunphy F R; Spitzer G; Buzdar A U; Hortobagyi G N; Horwitz L J; Yau J C; Spinolo J A; Jagannath S; Holmes F; Wallerstein R O
Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1207-16.
-
1990: Yau J C; LeMaistre C F; Zagars G K; Williams L A; Meneghetti C M; Luke D R; Dunphy F R; Spinolo J A; Jagannath S; Spitzer G
Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
Bone marrow transplantation 1990;5(4):269-72.
-
1990: Yau J C; Reading C L; Thomas M W; Davaraj B M; Tindle S E; Jagannath S; Dicke K A
Purging of T-lymphocytes with magnetic affinity colloid.
Experimental hematology 1990;18(3):219-22.
-
1990: Spinolo J A; Dicke K A; Horwitz L J; Jagannath S; Zander A R; Auber M L; Spitzer G
Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia.
Bone marrow transplantation 1990;5(2):111-8.
-
1990: Spitzer G; Deisseroth A; Ventura G; Jagannath S; Fogel B; Taylor K; Huan S; Dunphy F; Dicke K; Souza L
Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy.
International journal of cell cloning 1990;8 Suppl 1():249-59; discussion 259-61.
-
1989: Taylor K M; Jagannath S; Spitzer G; Spinolo J A; Tucker S L; Fogel B; Cabanillas F F; Hagemeister F B; Souza L M
Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1791-9.
-
1989: Velasquez W S; Jagannath S; Tucker S L; Fuller L M; North L B; Redman J R; Swan F; Hagemeister F B; McLaughlin P; Cabanillas F
Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data.
Blood 1989;74(2):551-7.
-
1989: Jagannath S; Armitage J O; Dicke K A; Tucker S L; Velasquez W S; Smith K; Vaughan W P; Kessinger A; Horwitz L J; Hagemeister F B
Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(2):179-85.
-
1989: Horwitz L J; Kantarjian H M; Jagannath S; Keating M J; McCredie K B; Spitzer G; Vellekoop L; Zander A R; Dicke K A
Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia.
Bone marrow transplantation 1989;4(1):101-5.
-
1989: Spinolo J A; Jagannath S; Dicke K A; Smith K E; Cabanillas F; Hagemeister F B; Horwitz L J; McLaughlin P; Swan F; Spitzer G
High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experience.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():233-8.
-
1988: Zander A R; Keating M; Dicke K; Dixon D; Pierce S; Jagannath S; Peters L; Horwitz L; Cockerill K; Spitzer G
A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(10):1548-57.
-
1988: Cabanillas F; Velasquez W S; McLaughlin P; Jagannath S; Hagemeister F B; Redman J R; Swan F; Rodriguez M A
Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Seminars in hematology 1988;25(2 Suppl 2):47-50.
-
1988: Velasquez W S; Cabanillas F; Salvador P; McLaughlin P; Fridrik M; Tucker S; Jagannath S; Hagemeister F B; Redman J R; Swan F
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).
Blood 1988;71(1):117-22.
-
1987: Zander A R; Culbert S; Jagannath S; Spitzer G; Keating M; Larry N; Cockerill K; Hester J; Horwitz L; Vellekoop L
High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia.
Cancer 1987;59(6):1083-6.
-
1987: Jagannath S; Reading C L; Dicke K A; Tindle S; Devaraj B; Tucker S L; Spitzer G
Clinical application of Percoll gradient-separated bone marrow.
Bone marrow transplantation 1987;1(3):281-8.
-
1987: Dicke K A; Jagannath S; Walters R S; Horwitz L J; Spitzer G
The role of autologous bone marrow transplantation in acute leukemia.
Annals of the New York Academy of Sciences 1987;511():468-72.
-
1986: Vellekoop L; Jagannath S; Spitzer G; Zander A R; Horwitz L J; Keating M; McCredie K B; Dicke K A
High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse.
American journal of clinical oncology 1986;9(4):307-10.
-
1986: Armitage J O; Jagannath S; Spitzer G; Bierman P; Kessinger A; Kumar P; Cabanillas F; Zander A; Vellekoop L; Dicke K A
High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma.
European journal of cancer & clinical oncology 1986;22(7):871-7.
-
1986: Spitzer G; Jagannath S; Dicke K A; Armitage J; Zander A R; Vellekoop L; Horwitz L; Cabanillas F; Zagars G K; Velasquez W S
High-dose melphalan and total body irradiation with bone marrow transplantation for refractory malignancies.
European journal of cancer & clinical oncology 1986;22(6):677-84.
-
1986: Jagannath S; Dicke K A; Armitage J O; Cabanillas F F; Horwitz L J; Vellekoop L; Zander A R; Spitzer G
High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
Annals of internal medicine 1986;104(2):163-8.
-
1985: Zander A R; Dicke K A; Keating M; Vellekoop L; Culbert S; Spitzer G; Kanojia M; Jagannath S; Schell S; Hester J
Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy.
Cancer 1985;56(6):1374-9.
-
1985: Dicke K A; Vellekoop L; Zander A; Jagannath S; Poynton C; Lichtiger B; Verma D S; Spitzer G
Autologous bone marrow transplantation in acute leukemia.
Survey and synthesis of pathology research 1985;4(1):84-96.
-
1984: Dicke K A; Jagannath S; Spitzer G; Poynton C; Zander A; Vellekoop L; Reading C L; Jehn U W; Tindle S
The role of autologous bone marrow transplantation in various malignancies.
Seminars in hematology 1984;21(2):109-22.
-
1984: Kanojia M D; Anagnostou A A; Zander A R; Vellekoop L; Spitzer G; Verma D S; Jagannath S; Dicke K A
High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults.
Transplantation 1984;37(3):246-9.
-
1984: Kurzrock R; Zander A; Kanojia M; Vellekoop L; Spitzer G; Jagannath S; Schell S; Peters L; Dicke K
Obstructive lung disease after allogeneic bone marrow transplantation.
Transplantation 1984;37(2):156-60.
-
1983: Tannir N M; Spitzer G; Zander A R; Jagannath S; Kanojia M; Vellekoop L; McLaughlin P; Hagemeister F J; Dicke K A
High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma.
European journal of cancer & clinical oncology 1983;19(8):1091-6.
-
1983: Dicke K A; Tindle S E; Davis F M; Jagannath S; Tucker S; Lilien M; van Leeuwen P; Verma D S; Vellekoop L
Leukemic cell colony formation in soft agar by bone marrow cells and peripheral blood cells from untreated acute leukemia patients.
Experimental hematology 1983;11(4):341-50.
-
1983: Poynton C H; Dicke K A; Culbert S; Frankel L S; Jagannath S; Reading C L
Immunomagnetic removal of CALLA positive cells from human bone marrow.
Lancet 1983;1(8323):524.
Sign-in to see more
